{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-042644","form_type":"8-K","ticker":"ELDN","cik":"0001404281","company_name":"Eledon Pharmaceuticals, Inc.","filed_at":"2025-03-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.533518+00:00","generated_at":"2026-05-24T09:55:04.584530+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Eledon Q4 net loss $44.6M; cash runway extended; tegoprubart used in pig kidney transplant","bullets":["Q4 2024 net loss $44.6M ($0.64/shr) vs $30.1M ($1.00/shr) in Q4 2023; includes non-cash warrant loss $20.9M.","FY 2024 net loss $36.2M vs $116.5M in 2023; excluding warrant changes, net loss $67.1M vs $40.3M.","Cash $140.2M at Dec 31, 2024; $85M oversubscribed offering extends runway to end of 2026.","Tegoprubart used in second genetically modified pig kidney transplant (Jan 25, 2025) at Mass General; patient off dialysis.","Positive initial data on islet transplant recipients; insulin independence without tacrolimus; topline Ph2 BESTOW due Q4 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-042644","json":"https://secwatch.observer/filing/0000950170-25-042644.json","markdown":"https://secwatch.observer/filing/0000950170-25-042644.md","text":"https://secwatch.observer/filing/0000950170-25-042644.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1404281/000095017025042644/0000950170-25-042644-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1404281/000095017025042644/eldn-20250320.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T09:55:04.584530+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}